Unknown

Dataset Information

0

Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.


ABSTRACT: Lack of adherence, inaccessibility to viral reservoirs, long-term drug toxicities, and treatment failures are limitations of current antiretroviral therapy (ART). These limitations lead to increased viral loads, medicine resistance, immunocompromise, and comorbid conditions. To this end, we developed long-acting nanoformulated ART (nanoART) through modifications of existing atazanavir, ritonavir, and efavirenz suspensions in order to establish cell and tissue drug depots to achieve sustained antiretroviral responses. NanoART's abilities to affect immune and antiviral responses, before or following human immunodeficiency virus type 1 infection were tested in nonobese severe combined immune-deficient mice reconstituted with human peripheral blood lymphocytes. Weekly subcutaneous injections of drug nanoformulations at doses from 80 mg/kg to 250 mg/kg, 1 day before and/or 1 and 7 days after viral exposure, elicited drug levels that paralleled the human median effective concentration, and with limited toxicities. NanoART treatment attenuated viral replication and preserved CD4(+) Tcell numbers beyond that seen with orally administered native drugs. These investigations bring us one step closer toward using long-acting antiretrovirals in humans.

SUBMITTER: Roy U 

PROVIDER: S-EPMC3570176 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

Roy Upal U   McMillan JoEllyn J   Alnouti Yazen Y   Gautum Nagsen N   Smith Nathan N   Balkundi Shantanu S   Dash Prasanta P   Gorantla Santhi S   Martinez-Skinner Andrea A   Meza Jane J   Kanmogne Georgette G   Swindells Susan S   Cohen Samuel M SM   Mosley R Lee RL   Poluektova Larisa L   Gendelman Howard E HE  

The Journal of infectious diseases 20120717 10


Lack of adherence, inaccessibility to viral reservoirs, long-term drug toxicities, and treatment failures are limitations of current antiretroviral therapy (ART). These limitations lead to increased viral loads, medicine resistance, immunocompromise, and comorbid conditions. To this end, we developed long-acting nanoformulated ART (nanoART) through modifications of existing atazanavir, ritonavir, and efavirenz suspensions in order to establish cell and tissue drug depots to achieve sustained ant  ...[more]

Similar Datasets

| S-EPMC3987826 | biostudies-other
| S-EPMC4024396 | biostudies-literature
| S-EPMC3401515 | biostudies-literature
| S-EPMC6403019 | biostudies-literature
| S-EPMC4696780 | biostudies-literature
| S-EPMC5926202 | biostudies-literature
| S-EPMC5330738 | biostudies-literature
| S-EPMC5035742 | biostudies-literature
| S-EPMC3065529 | biostudies-literature
| S-EPMC5745520 | biostudies-literature